Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 12/31/03
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 10/31/02
End: -
Due: -
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Myocet, Docetaxel & Trastuzumab as 1st Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer | NCT00250874 | Zeneus Pharma | user2@example.com | None | 2003-12-31 | - | - | - | - | 2025-07-14 |
| Open Label, Single Arm, Phase II Study Using R-COMP in Elderly Patients With Aggressive NHL. | NCT00244127 | Zeneus Pharma | user2@example.com | None | 2002-10-31 | - | - | - | - | 2025-07-14 |